Clinical-stage biopharmaceutical company Hoth Therapeutics Inc (NASDAQ:HOTH) on Monday reported positive data from its HT-VA study, conducted under its Cooperative Research and Development Agreement (CRADA) with the US Department of Veterans Affairs and Emory University, demonstrating that parenteral GDNF (Glial Cell-Derived Neurotrophic Factor) directly reprograms liver fat metabolism at the genetic level in a preclinical model of metabolic-associated fatty liver disease (MAFLD).
According to the company, the data highlights statistically significant improvements in key genes responsible for fat production and fat metabolism, positioning GDNF as a potentially differentiated therapeutic approach targeting the root cause of fatty liver disease and metabolic dysfunction.
Next, Hoth plans to advance the HT-VA findings into additional preclinical validation studies, evaluate clinical development pathways for metabolic and liver diseases, and explore strategic partnerships and collaborations to accelerate development.
Ascletis announces submission of US IND application for oral obesity combination therapy
AstraZeneca acquires biotechnology company Omniose to strengthen vaccine capabilities
Medivir secures US patent protection for fostrox and lenvatinib combination until 2044
PharmaLogic to acquire CDMO business and manufacturing facility from Lantheus
Ribo submits European Clinical Trial Application for SR122 in mixed and severe dyslipidaemia
Spermosens and Genea agree IVF study of JUNO-Checked in Australia
Janux reports positive Phase 1 data for JANX011, plans autoimmune trials in 2027
Illumina expands MRD research portfolio with ultrasensitive sequencing technology
Compass Pathways completes FDA application for COMP360 in treatment-resistant depression
Charles River Laboratories to acquire Frontage bioanalysis and DMPK businesses for USD470m
UCB and Biogen report additional positive Phase 3 data for investigational lupus treatment